NRX Pharmaceuticals Inc (NRXP)
0.4719
-0.06
(-10.96%)
USD |
NASDAQ |
Mar 28, 16:00
0.4779
+0.01
(+1.27%)
After-Hours: 20:00
NRX Pharmaceuticals Total Liabilities (Quarterly): 19.33M for Sept. 30, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
Date | Value |
---|---|
September 30, 2023 | 19.33M |
June 30, 2023 | 22.62M |
March 31, 2023 | 22.06M |
December 31, 2022 | 18.41M |
September 30, 2022 | 8.042M |
June 30, 2022 | 7.081M |
Date | Value |
---|---|
March 31, 2022 | 11.91M |
December 31, 2021 | 11.92M |
September 30, 2021 | 36.28M |
June 30, 2021 | 35.98M |
December 31, 2020 | 46.71M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
7.081M
Minimum
Jun 2022
46.71M
Maximum
Dec 2020
21.85M
Average
19.33M
Median
Sep 2023
Total Liabilities (Quarterly) Benchmarks
CEL-SCI Corp | 16.06M |
AIM ImmunoTech Inc | 5.259M |
IGC Pharma Inc | 2.206M |
NovaBay Pharmaceuticals Inc | 5.815M |
Protalix BioTherapeutics Inc | 50.86M |
Total Liabilities (Quarterly) Related Metrics
Total Assets (Quarterly) | 13.11M |
Shareholders Equity (Quarterly) | -6.217M |